AstraZeneca on Monday issued a statement defending its COVID-19 vaccine after some countries expressed concern about blood clots in vaccines and called for a temporary suspension.
The company said there was “no evidence of an increased risk” of blood clots after getting a jab.
Ireland announced on Sunday that it would temporarily halt the distribution of the vaccine “out of caution”, Reuters reported. The move was announced after reports of blood clots at some recipients in Norway.
AstraZeneca, the company in Cambridge, UK, said more than 17 million people had been vaccinated with the shots in the European Union and the UK, and there was no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia. , in any defined age group, gender, group or any specific country. “
The statement pointed to cases of pulmonary embolisms and said that the number of cases after receiving the shot “is much lower than would be expected to occur naturally in a general population of this magnitude and is similar to other licensed COVIDs”. 19 vaccines. “
The Netherlands followed Ireland late Sunday and announced that it would suspend vaccinations with the AstraZeneca shot for two weeks. The health ministry said the move follows six new reports in Denmark and Norway on blood clotting and lower platelet levels in people under 50.
DENMARK SUSPENSES USE OF ASTRAZENECA’S COVID-19 SUBSTITUTES NEXT REPORT OF BLOODS
The Dutch medicine authority also emphasized that no connection had been established between the cases and the vaccine.
CLICK HERE TO GET THE FOX NEWS APP
The World Health Organization and the European Union’s medicine regulator have previously said there is no link between the jab and an increased risk of developing a blood clot.
Associated Press contributed to this report